Question explored with the scientific record
JARDIANCE is proven to lower the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, when the heart cannot pump enough blood to the rest of the bod
The short version: JARDIANCE cuts heart-failure hospitalizations in adults with heart failure. It does not reliably cut cardiovascular death, and the claim as stated overstates the death benefit.
The strongest evidence is in people whose hearts pump poorly (reduced ejection fraction). In EMPEROR-Reduced, empagliflozin lowered the combined risk of cardiovascular death or heart-failure hospitalization from 24.7% to 19.4% [6][3]. That is about 5 fewer events per 100 people treated, roughly one prevented for every 20 treated [3][4]. The benefit held with or without diabetes [2][6].
The death claim is weaker. In people with preserved pumping (HFpEF), the combined endpoint improved but cardiovascular death alone was not significantly reduced [1][5]. A pooled analysis found a modest cardiovascular mortality reduction overall, but in HFpEF alone it did not reach significance [7]. The trials were manufacturer-run and mostly used combined endpoints, which can hide a null death result inside a positive hospitalization result.
| Trial | Population | Combined endpoint | CV death alone |
|---|---|---|---|
| EMPEROR-Reduced | Reduced pumping | 19.4% vs 24.7% [6] | Not separated here |
| EMPEROR-Preserved | Preserved pumping | HR 0.79 [1] | Not significantly reduced [1] |
| DELIVER | Preserved pumping | HR 0.82 [1] | Not significant [5] |
Known harms include genital infections, low blood pressure, and rare ketoacidosis and Fournier gangrene [1][4]. Long-term safety beyond a few years is not in these records.
My call: proven to reduce heart-failure hospitalization, not proven to reduce cardiovascular death on its own, and the label's death claim is stronger than the trial data supports. Confidence: moderate.
Sources used 7
-
Sglt-2 Inhibitors: A Useful Addition for Treatment of Heart Failure with Mildly Preserved and Preserved Ejection Fraction
A critical review of the role of SGLT2 inhibitors (empagliflozin and dapagliflozin) in heart failure with mildly preserved or preserved ejection fraction (HFpEF/HFpEF), highlighting early CV benefit in EMPEROR-Preserved and DELIVER trials, lack of consistent CV death reduction, …
DOI: 10.31579/2693-4779/114 -
SGLT2 Inhibitors: A Promising New Tool in Cardiology
SGLT2 inhibitors have demonstrated cardiovascular benefits extending beyond glucose control, showing reduced major adverse events in type 2 diabetes and significant benefits in heart failure patients, though consistency varies across trials.
DOI: 10.33140/ijdmd.08.03.09 -
Sodium-Glukose-Transporter 2(SGLT2)-Hemmer bei Herzinsuffizienz
ESC 2021 guidelines endorse SGLT2 inhibitors as first-line therapy for heart failure with reduced ejection fraction, summarizing DAPA-HF and EMPEROR-Reduced which show around a 5% absolute reduction in the primary endpoint (HF hospitalization or cardiovascular death) with benefi…
DOI: 10.1007/s12181-021-00524-2 -
SGLT-hemlar – Nýir meðferðarmöguleikar við langvinnum nýrnasjúkdómi og hjartabilun
This narrative review concludes that SGLT2 inhibitors reduce cardiovascular and renal events in heart failure and chronic kidney disease, with benefits across ejection fractions and diabetes status, while requiring vigilance for rare ketoacidosis and Fournier gangrene.
DOI: 10.17992/lbl.2024.12.817 -
Eficácia dos Inibidores de SGLT2 na Redução de Eventos Cardiovasculares Maiores em Pacientes com Insuficiência Cardíaca com Fração de Ejeção Preservada: Revisão Sistemática de Literatura
Empagliflozin and dapagliflozin reduce major adverse cardiovascular events and heart-failure hospitalizations in HFpEF, with less robust evidence for reducing cardiovascular mortality.
DOI: 10.51473/rcmos.v1i2.2025.1679 -
Use of SGLT-2 Inhibitors in Patients with Chronic Kidney Disease
This CME supplement reviews evidence that SGLT-2 inhibitors reduce heart failure and kidney outcomes in high-risk patients, and summarizes guideline-based guidance for shingles vaccination, asthma, COPD, obesity, aspirin, statins, type 1 diabetes screening, CKD, and CGM.
DOI: 10.12788/jfp.0225 -
Efficacy of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in Heart Failure Management: A Narrative Review
This narrative review reports pooled randomized-trial estimates that SGLT2 inhibitors reduce heart failure hospitalizations and cardiovascular mortality overall, with greater benefit in HFrEF and limited HFpEF mortality benefit.
DOI: 10.61919/jhrr.v4i3.1573